Further studies also demonstrated that postmenopausal women with osteoporosis exhibit lower levels of sclerostin than healthy controls85,87,88 and an increase in circulating sclerostin levels after risedronate treatment in patients with osteoporosis87. The gene discussed is SOST; the disease is osteoporosis.